This review examines novel therapeutic targets in Parkinson’s disease, suggesting multifactorial interventions may alter disease progression.
Key Points
Parkinson’s disease is primarily characterized by dopaminergic neuron loss in the substantia nigra, leading to severe motor symptoms.
Recent perspectives indicate that therapy should address multiple factors—like neuroinflammation and mitochondrial dysfunction—instead of just dopamine levels.
Emerging therapeutic approaches explore mitochondrial health, autophagy, and α-synuclein aggregation, aiming for disease modification rather than mere symptoms management.
The transition towards treatments that promise to halt or reverse disease progression enhances hope for both patients and healthcare providers.